The third annual BIO India International Conference will be held September 12-13 at the Grand Hyatt in Mumbai, India. BIO India will feature high-level keynote speakers, education panels on the latest trends, networking opportunities, company presentations and partnering meeting opportunities through the BIO One-on-One Partnering™ system.
The event is particularly relevant and timely for those looking to learn more about India’s rapidly growing global presence in the life sciences. Read more to learn the top five reasons to attend!
- India’s biotechnology sector includes more than 325 companies and some with revenues in the billions of dollars. According to the BioSpectrum-ABLE Biotech Industry Survey of 2011, the industry has grown by 21.5% in 2006-2011, surging to $4 billion. Additionally, India’s government plans a major boost to its health sector, targeting investments of 2.5% of GDP by 2017, up from the current 1.4%.
- In the 2012 Scientific American Worldview report, India was among the countries recently named as likely to have the strongest gains in developing next generation life-saving products in the coming decade. Due to the colossal increase in capital, a well-educated population and India’s existing biotech and pharmaceutical companies, research is expected to move progressively towards India, especially as the demand for improved healthcare increases.
- The number and type of collaborations between Indian and US or EU companies has grown rapidly in the past few years. In 2012 alone there have been seven deals involving India companies with such big names as AstraZeneca, Merck KGaA and Abbott.
- The 2011 BIO India International Conference saw delegates schedule over 500 partnering meetings and featured presentations from 17 top India, U.S. and European biotech companies.
- India is the world’s largest manufacturer of vaccines and the growth of India vaccine makers arises from their ability to develop and produce high-quality vaccines with low manufacturing costs, which have been primarily marketed in the developing world. India’s vaccine market could grow from its current $250M to $1.7B by 2020, and could even reach $3.5B in a high-growth scenario.
Don’t just take it from us, hear Kiran Mazumdar-Shaw, Chairman, Biocon, discuss the growing momentum and visibility of the third annual BIO India International Conference.
BIO’s partner in India is the Association of Biotechnology Led Enterprises (ABLE), which represents Indian and Asian biotechnology and pharmaceutical companies, as well as leading investment banks and venture capital firms. ABLE is to co-host this dynamic event for a third consecutive year.
For program, partnering and registration information on the BIO India International Conference, please visit here.